よむ、つかう、まなぶ。
04 参考資料１－１23価肺炎球菌莢膜ポリサッカライドワクチン（肺炎球菌ワクチン）ファクトシート (30 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36630.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第22回 12／1）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Vaccine. 31:3577-3584, 2013.
40．Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, et al. Immunogenicity
and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and
older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine.
31:3585-3593, 2013.
41．Namkoong H, Funatsu Y, Oishi K, Akeda Y, Hiraoka R, Takeshita K, et al. Comparison of the
immunogenicity and safety between polysaccharide and protein-conjugated pneumococcal
vaccines among the elderly aged 80 years or older in Japan: An open-labeled randomized
study. Vaccine 33:327-332, 2015.
42．Ohshima N, et al. Sustained functional serotype-specific antibody after primary and
secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with
chronic lung disease. Vaccine 32:1181-6,2014.
43．Törling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent
pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated
for pneumonia. Vaccine 22:96–103,2003.
44．Kawakami K, Kishino H, Kanazu S, Toshimizu N, Takahashi K, Sterling T, et al. Revaccination
with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well
tolerated and elicits immune responses. Vaccine 34:3875-81,2016.
45．Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, et al. Repeat
revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–
74 years living in Alaska: No evidence of hyporesponsiveness.
Vaccine. 29：2287―95,2011.
46．Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent
pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among
adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR 63(37):822-5,2014.
47．Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, et al. Sequential
administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal
polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine.
32:2364-2374, 2014.
29
Vaccine. 31:3577-3584, 2013.
40．Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, et al. Immunogenicity
and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and
older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine.
31:3585-3593, 2013.
41．Namkoong H, Funatsu Y, Oishi K, Akeda Y, Hiraoka R, Takeshita K, et al. Comparison of the
immunogenicity and safety between polysaccharide and protein-conjugated pneumococcal
vaccines among the elderly aged 80 years or older in Japan: An open-labeled randomized
study. Vaccine 33:327-332, 2015.
42．Ohshima N, et al. Sustained functional serotype-specific antibody after primary and
secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with
chronic lung disease. Vaccine 32:1181-6,2014.
43．Törling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent
pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated
for pneumonia. Vaccine 22:96–103,2003.
44．Kawakami K, Kishino H, Kanazu S, Toshimizu N, Takahashi K, Sterling T, et al. Revaccination
with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well
tolerated and elicits immune responses. Vaccine 34:3875-81,2016.
45．Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, et al. Repeat
revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–
74 years living in Alaska: No evidence of hyporesponsiveness.
Vaccine. 29：2287―95,2011.
46．Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent
pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among
adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR 63(37):822-5,2014.
47．Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, et al. Sequential
administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal
polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine.
32:2364-2374, 2014.
29